145 related articles for article (PubMed ID: 28139560)
1. [Role of fibroblast growth factor 23 in the development of cardiovascular diseases in patients with end-stage renal failure on programmed hemodialysis].
Dzgoeva FU; Sopoev MY; Bestaeva TL; Khamitsaeva OV; Ktsoeva FA; Sageeva RO
Ter Arkh; 2016; 88(12):51-56. PubMed ID: 28139560
[TBL] [Abstract][Full Text] [Related]
2. Correlation between hypervolemia, left ventricular hypertrophy and fibroblast growth factor 23 in hemodialysis patients.
Unver S; Kavlak E; Gümüsel HK; Celikbilek F; Esertas K; Muftuoglu T; Kirilmaz A
Ren Fail; 2015 Jul; 37(6):951-6. PubMed ID: 26030798
[TBL] [Abstract][Full Text] [Related]
3. [Fibroblast growth factor 23 and a novel high-sensitivity troponin I: Early markers and alternative ways of damaging the heart in chronic kidney disease].
Dzgoeva FU; Sopoev MY; Gatagonova TM; Bestaeva TL; Khamitsaeva OV
Ter Arkh; 2015; 87(6):68-74. PubMed ID: 26281199
[TBL] [Abstract][Full Text] [Related]
4. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
Milovanova LY; Milovanov YS; Kudryavtseva DV; Markina MM; Milovanova SY; Kozlovskaya LV; Lebedeva MV; Beketov VD; Moiseev SV; Mukhin NA; Fomin VV; Svistunov AA
Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
[TBL] [Abstract][Full Text] [Related]
5. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
Milovanova LY; Kozlovskaya LV; Markina MM; Milovanova SY; Borisov AA; Mukhin NA; Fomin VV; Moiseev SV
Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
[TBL] [Abstract][Full Text] [Related]
6. [New markers of cardio-renal links in chronic kidney disease].
Milovanova LIu; Milovanov IuS; Kozlovskaia LV; Mukhin NA
Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis.
Knap B; Večerić-Haler Ž; Benedik M; Buturović-Ponikvar J; Ponikvar R; Bren AF
Ther Apher Dial; 2013 Aug; 17(4):407-11. PubMed ID: 23931880
[TBL] [Abstract][Full Text] [Related]
8. Relation of fibroblast growth factor-23 and cardiovascular calcification in end-stage kidney disease patients on regular hemodialysis.
El Baz TZ; Khamis OA; Ahmed Gheith OA; Abd Ellateif SS; Abdallah AM; Abd El Aal HC
Saudi J Kidney Dis Transpl; 2017; 28(1):51-60. PubMed ID: 28098103
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
Milovanova LY; Dobrosmyslov IA; Milovanov YS; Taranova MV; Kozlov VV; Milovanova SY; Kozevnikova EI
Ter Arkh; 2018 Jun; 90(6):48-54. PubMed ID: 30701904
[TBL] [Abstract][Full Text] [Related]
10. [Left ventricular systolic and diastolic dysfunction in patients with chronic renal failure treated with hemodialysis].
Wanic-Kossowska M; Lehmann P; Czekalski S
Pol Arch Med Wewn; 2003 Apr; 109(4):365-73. PubMed ID: 12931488
[TBL] [Abstract][Full Text] [Related]
11. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
12. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
13. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A
J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
[TBL] [Abstract][Full Text] [Related]
14. The value of serum FGF-23 as a cardiovascular marker in HD patients.
Sany D; Elsawy AE; Aziz A; Elshahawy Y; Ahmed H; Aref H; El Rahman MA
Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):44-52. PubMed ID: 24434381
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation.
Eser B; Yayar O; Buyukbakkal M; Erdogan B; Ercan Z; Merhametsiz O; Haspulat A; Oğuz EG; Dogan İ; Canbakan B; Ayli MD
Nefrologia; 2015; 35(5):465-72. PubMed ID: 26394828
[TBL] [Abstract][Full Text] [Related]
16. [Osteoprotegerin and fibroblast growth factor 23 in the development of cardiovascular events in chronic kidney disease].
Dzgoeva FU; Gatagonova TM; Bestaeva TL; Sopoev MIu; Bazaeva BG; Khamitsaeva OV
Ter Arkh; 2014; 86(6):63-9. PubMed ID: 25095658
[TBL] [Abstract][Full Text] [Related]
17. Radiographic assessment of vascular calcification, aortic pulse wave velocity, ankle-brachial index and fibroblast growth factor-23 in chronic hemodialysis patients.
Breznik S; Ekart R; Hren M; Rupreht M; Balon BP
Ther Apher Dial; 2013 Aug; 17(4):378-83. PubMed ID: 23931875
[TBL] [Abstract][Full Text] [Related]
18. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart.
Ford ML; Smith ER; Tomlinson LA; Chatterjee PK; Rajkumar C; Holt SG
Nephrol Dial Transplant; 2012 Feb; 27(2):727-33. PubMed ID: 21750158
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional association of volume, blood pressures, and aortic stiffness with left ventricular mass in incident hemodialysis patients: the Predictors of Arrhythmic and Cardiovascular Risk in End-Stage Renal Disease (PACE) study.
Kim ED; Sozio SM; Estrella MM; Jaar BG; Shafi T; Meoni LA; Kao WH; Lima JA; Parekh RS
BMC Nephrol; 2015 Aug; 16():131. PubMed ID: 26249016
[TBL] [Abstract][Full Text] [Related]
20. FGF-23 in patients with end-stage renal disease on hemodialysis.
Imanishi Y; Inaba M; Nakatsuka K; Nagasue K; Okuno S; Yoshihara A; Miura M; Miyauchi A; Kobayashi K; Miki T; Shoji T; Ishimura E; Nishizawa Y
Kidney Int; 2004 May; 65(5):1943-6. PubMed ID: 15086938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
